| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 2 | +15.9K | 100% | $8.63 | +$137K |
| Sells | 0 | ||||
| Net | +2 | +15.9K | 100% | +$137K |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc. | Director | $47.4M | 05 May 2025 | ||
| STEVEN SALAMON | Director | $47.4M | 15 May 2025 | ||
| Gil Aharon | Director | $47.4M | 15 May 2025 | ||
| GERARD MICHEL | CHIEF EXECUTIVE OFFICER, Director | $2.82M | +$98K | +3.6% | 11 Nov 2025 |
| Vojo Vukovic | Chief Medical Officer | $807K | 12 Jun 2025 | ||
| David Hoffman | Gen'l Counsel, Cco & Secy | $277K | 07 Feb 2025 | ||
| Sandra Pennell | Chief Financial Officer | $227K | 07 Feb 2025 | ||
| John Richard Sylvester | Director | $133K | +$39K | +41.6% | 21 Nov 2025 |
| John Purpura | Chief Operating Officer | $125K | 08 Feb 2023 | ||
| Kevin Muir | Gm Interventional Oncology | $69.1K | 07 Feb 2025 | ||
| Christine Padula | Interim Principal Accounting Officer | 01 Sep 2021 | |||
| Bridget Martell | Director | 15 May 2025 | |||
| ROGER G. STOLL PHD | Director | 23 May 2024 | |||
| Martha S. Rook | Chief Operating Officer | 07 Feb 2025 | |||
| Johnny John | Svp Clinical Dev & Med Affairs | 08 Feb 2023 | |||
| ELIZABETH CZEREPAK | Director | 15 May 2025 | |||
| Anthony Dias | Vp Finance | 08 Feb 2023 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|